Luminex Corporation LMNX reported second-quarter 2020 adjusted earnings of 27 cent per share (EPS), beating the Zacks Consensus Estimate of 8 cents. The company had reported loss per share of 11 cents in the year-ago period.
Revenues came in at $109.5 million, missing the Zacks Consensus Estimate by a marginal 0.1%. However, the top line improved 31.8% on a year-over-year basis.
Total sample-to-answer molecular diagnostics revenues grew more than 100% from the prior-year quarter.
Revenues at this segment totaled $15.5 million, down16.7% from the year-ago quarter.
This segment accounted for $11.3 million of revenues, down 11% year over year.
Royalty revenues totaled $12.1 million, down 5.5% on a year-over-year basis.
This segment reported revenues worth $61.2 million, up 94.9% on a year-over-year basis.
Revenues at the segment amounted to $5.5 million, down 8.3% from the year-ago quarter.
Other revenues came in at $3.9 million, up 160% from the prior-year quarter.
Luminex Corporation Price, Consensus and EPS Surprise
Luminex Corporation price-consensus-eps-surprise-chart | Luminex Corporation Quote
The company exited second quarter with cash and cash equivalents of $291.7 million, up from $43.1 million on a sequential basis.
Cumulative net cash provided by operating activities at the end of the second quarter of 2020 came in at $24.1 million against cumulative net cash used in operating activities of $1.2 million in the year-ago period.
Gross profit in the reported quarter was $69.7 million, up 54.1% year over year. Gross margin was 63.6%, expanding 917 basis points (bps).
The company reported adjusted operating profit of $21.6 million against the year-ago quarter’s adjusted operating loss of $2.9 million. Adjusted operating margin came in at 19.7%, highlighting an expansion of 2324 bps.
Luminex projects third-quarter 2020 revenues at or above $100 million, suggesting growth above 26% from the figure reported in third-quarter 2019.The Zacks Consensus estimate for the same is pegged at $93.3 million.
Revenues for 2020 are estimated at or above $415 million, reflecting growth of more than 24% from figure reported in 2019. The Zacks Consensus estimate for the same is pegged at $407.4 million.
It is important to note here that the company expects to present an updated full-year revenue outlook in its third-quarter earnings release.
Luminex exited the second quarter on a mixed note. The company continues to gain from its flagship ARIES and VERIGENE platforms that currently have a strong customer base. Also, the company witnessed total sample-to-answer molecular diagnostics revenue growth in the quarter. Expansion of both margins is a positive. Notably, in April, the company received U.S. FDA Emergency Use Authorization for the ARIES SARS-CoV-2 Assay.
However, revenues at each operating segment other than Assay and Other segments declined in the quarter.
Zacks Rank and Other Key Picks
Currently, Luminex carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Thermo Fisher Scientific Inc. TMO, PerkinElmer, Inc. PKI and OPKO Health, Inc. OPK. While PerkinElmer sports a Zacks Rank #1 (Strong Buy), the other two sport a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher reported second-quarter 2020 adjusted EPS of $3.89, beating the Zacks Consensus Estimate by 45.7%. Revenues of $6.92 billion outpaced the consensus mark by 0.1%.
PerkinElmer reported second-quarter 2020 adjusted EPS of $1.57, surpassing the Zacks Consensus Estimate by 68.8%. Revenues of $811.7 million outpaced the consensus mark by 1.3%.
OPKO Health reported second-quarter 2020 EPS of 5 cents against the Zacks Consensus Estimate of a loss of 7 cents per share. Revenues of $301.2 million surpassed the consensus estimate by 28.4%.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Luminex Corporation (LMNX) : Free Stock Analysis Report
PerkinElmer, Inc. (PKI) : Free Stock Analysis Report
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
OPKO Health, Inc. (OPK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research